--- title: "A single pen covering the full month's dosage! Eli Lilly launches Zepbound multi-dose injection pen starting at $299" description: "On Monday, Eli Lilly launched the Zepbound multi-dose KwikPen injection device, allowing patients to complete four doses in a month with just one pen, significantly reducing the number of devices used" type: "news" locale: "en" url: "https://longbridge.com/en/news/276630276.md" published_at: "2026-02-23T23:17:32.000Z" --- # A single pen covering the full month's dosage! Eli Lilly launches Zepbound multi-dose injection pen starting at $299 > On Monday, Eli Lilly launched the Zepbound multi-dose KwikPen injection device, allowing patients to complete four doses in a month with just one pen, significantly reducing the number of devices used and enhancing convenience. This new formulation has received FDA approval for an expanded label and is sold to self-paying patients through the LillyDirect platform, with a minimum price of $299. As a result of this news, Eli Lilly's stock price rose over 5% during intraday trading on Monday Eli Lilly launched a new formulation of its blockbuster weight loss drug Zepbound on Monday. The new version comes in a single-pen format, providing a full month's supply. **Self-paying patients can purchase this multi-dose device, named KwikPen, through the company's direct-to-consumer website LillyDirect. The price for the lowest dose starts at $299 per month.** This injection pen may be more convenient for some patients as it reduces the number of devices needed each month. Patients can complete four weekly Zepbound injections with one pen. Currently, patients using this treatment regimen need to use a different single-dose auto-injector each week. Eli Lilly also offers single-dose vials of Zepbound, which require patients to draw the medication into a syringe for self-injection. As a result of this news, Eli Lilly's stock price rose over 5% during intraday trading on Monday. Media reports indicate that this release comes as Eli Lilly seeks to solidify Zepbound's early success. Since its launch at the end of 2023, demand for Zepbound has surged. LillyDirect has played a key role in driving Zepbound's growth, and the introduction of the new formulation on this platform may attract more patients. The strong growth of Zepbound has helped Eli Lilly capture a significant share of the weight loss drug market from competitor Novo Nordisk. Company data for the fourth quarter shows that Zepbound generated $4.2 billion in revenue in the U.S., a year-on-year increase of 122%. Eli Lilly stated in a press release that the U.S. Food and Drug Administration has approved the expansion of Zepbound's label indications to include the multi-dose device. KwikPen has previously been used for other medications, such as Eli Lilly's popular diabetes drug Mounjaro. Ilya Yuffa, Eli Lilly's Head of U.S. and Global Customer Capabilities, stated in a press release: > “As part of our commitment to support the obesity population in weight management, we are introducing the Zepbound KwikPen as a new option. This device has been used for other Eli Lilly medications globally and in the U.S. and has gained patient trust.” ### Related Stocks - [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md) - [ELIL.US - Direxion Daily LLY Bull 2X Shares](https://longbridge.com/en/quote/ELIL.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md) - [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md) - [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md) - [LLYX.US - Defiance Daily Target 2X Long LLY ETF](https://longbridge.com/en/quote/LLYX.US.md) - [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 禮來公司押注於多劑量 Zepbound 注射筆，以推動 GLP-1 藥物的保留 | 禮來推出了 Zepbound KwikPen，這是一種多劑量注射器，能夠容納一個月的 tirzepatide，旨在簡化 GLP-1 減肥藥用户的使用流程。對於自費患者，新款注射筆的價格為每月 299 美元，取代了傳統的單劑量格式，減少了包裝 | [Link](https://longbridge.com/en/news/276615033.md) | | 禮來公司將在美國推出多劑量減肥藥裝置 | 禮來已獲得 FDA 批准推出其減肥藥 Zepbound 的四劑量 KwikPen，售價為每月 299 美元。這款多劑量筆提供六種劑量選擇，同時也用於禮來的糖尿病藥物 Mounjaro。自 2023 年獲批以來，Zepbound 已超越諾和諾 | [Link](https://longbridge.com/en/news/276609508.md) | | 禮來公司將多劑量的 Zepbound 注射筆加入自費項目中 | 禮來公司在獲得 FDA 批准後，將多劑量的 Zepbound KwikPens 納入自費菜單。每支筆包含四劑，初始 2.5 毫克劑量的價格為 299 美元。該公司旨在將美國藥品價格與歐洲對齊，提供比之前價格低 50 美元的折扣。這一推出是禮 | [Link](https://longbridge.com/en/news/276610573.md) | | 諾和諾德公司因試驗受挫，股價下跌，抹去了 Wegovy 時代最後的收益 | 諾和諾德公司的股票在其肥胖藥物 CagriSema 試驗遇挫後暴跌超過 15%，該藥物未能與禮來的 tirzepatide 的療效相匹配。這一下降抹去了 Wegovy 上市帶來的收益，使諾和諾德的估值減少了約 4000 億美元。摩根大通的分 | [Link](https://longbridge.com/en/news/276594064.md) | | 美股盤前熱門交易：諾和諾德藥物失利，禮來盤前漲 4.01%！橋水增持信心加持 | 禮來盤前漲 4.01%；天睿祥盤前漲 74.55%；X3 盤前漲 40.15%；VenHub Global 盤前漲 38.69%。 | [Link](https://longbridge.com/en/news/276585617.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.